Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
Journal of Clinical Investigation · 01.07.2025 · 135 (13)
DOI: 10.1172/jci186425 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.07.2025. Verfasst von Philip N Newsome und 1 weiteren Autor:innen. Beteiligte Einrichtung: Roger Williams Institute of Liver Studies, School of Immunology & Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, F…. Hauptthemen laut MEDLINE: Fatty Liver, Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Metabolic dysfunction–associated steatohepatitis (MASH), the progressive inflammatory form of MASLD, is now a leading cause of chronic liver disease worldwide. Driven by obesity and type 2 diabetes, MASH significantly increases the risk of cirrhosis, hepatocellular carcinoma, and liver failure. While public health interventions remain essential, therapeutic strategies targeting metabolic dysfunction, inflammation, and fibrosis are urgently needed. This Review focuses on pharmacological treatments in advanced development, including incretin-based therapies (GLP-1, dual, and triple agonists), metabolic modulators (PPAR, FGF21, and THR-β agonists), and novel agents such as fatty acid synthase inhibitors. Current regulatory approval is based on histological end points, with increasing interest in noninvasive biomarkers and personalized treatment approaches. Recent trials with agents such as semaglutide, tirzepatide, survodutide, lanifibranor, pegozafermin, and resmetirom demonstrate substantial promise in resolving MASH and improving fibrosis, but unresolved issues remain regarding treatment duration, response heterogeneity, and long-term adherence. Genetic variants (e.g., PNPLA3 polymorphisms) and emerging molecular biomarkers may enhance stratification, while artificial intelligence is beginning to shape trial design and drug development. As the field moves toward combination therapies and precision medicine, the definition of therapeutic success will likely evolve to reflect both histological improvement and patient-reported outcomes. This Review provides a timely synthesis of the landscape, challenges, and future directions in MASH therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Roger Williams Institute of Liver Studies, School of Immunology & Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, Foundation for Liver Research and King's College Hospital, London, Unit…
- MASLD Research Center, Division of Gastroenterology and Hepatology, and.
- Division of Epidemiology, Department of Family Medicine and Public Health, UCSD, La Jolla, California, USA.
Förderung
- NIDDK NIH HHS
Zitieren
APA
Newsome, P. N., & Loomba, R. (2025). Therapeutic horizons in metabolic dysfunction–associated steatohepatitis. Journal of Clinical Investigation, 135(13). https://doi.org/10.1172/jci186425
Vancouver
Newsome PN, Loomba R. Therapeutic horizons in metabolic dysfunction–associated steatohepatitis. Journal of Clinical Investigation. 2025;135(13). doi:10.1172/jci186425
BibTeX
@article{Newsome2025,
author = {Newsome, Philip N and Loomba, Rohit},
title = {Therapeutic horizons in metabolic dysfunction–associated steatohepatitis},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {13},
doi = {10.1172/jci186425}
}
EUVIMED